Evogene : Corporate Presentation

This presentation contains "forward-looking statements" relating to future events, and Evogene Ltd. (the "Company"), may from time to time make other statements, regarding our outlook or expectations for future financial or operating results and/or other matters regarding or affecting us that are considered "forward-looking statements" as defined in the U.S. Private Securities Litigation Reform Act of 1995 (the "PSLRA") and other securities laws, as amended. Statements that are not statements of historical fact may be deemed to be forward-looking statements. Such forward- looking statements may be identified by the use of such words as "believe", "expect", "anticipate", "should", "planned", "estimated", "intend" and "potential" or words of similar meaning. We are using forward-looking statements in this presentation when we discuss our value drivers, commercialization efforts and timing, product development and launches, estimated market sizes and milestones, pipeline, as well as our capabilities and technology.

Such statements are based on current expectations, estimates, projections and assumptions, describe opinions about future events, involve certain risks and uncertainties which are difficult to predict and are not guarantees of future performance. Readers are cautioned that certain important factors may affect the Company's actual results and could cause such results to differ materially from any forward-looking statements that may be made in this presentation. Therefore, actual future results, performance or achievements, and trends in the future may differ materially from what is expressed or implied by such forward-looking statements due to a variety of factors, many of which are beyond our control, including, without limitation, the current war between Israel, Hamas and Hezbollah and any worsening of the situation in Israel such as further mobilizations or escalation in the northern border of Israel and those described in greater detail in Evogene's Annual Report on Form 20-F and in other information Evogene files and furnishes with the Israel Securities Authority and the U.S. Securities and Exchange Commission, including those factors under the heading "Risk Factors".

Except as required by applicable securities laws, we disclaim any obligation or commitment to update any information contained in this presentation or to publicly release the results of any revisions to any statements that may be made to reflect future events or developments or changes in expectations, estimates, projections and assumptions.

The information contained herein does not constitute a prospectus or other offering document, nor does it constitute or form part of any invitation or offer to sell, or any solicitation of any invitation or offer to purchase or subscribe for, any securities of Evogene or the Company, nor shall the information or any part of it or the fact of its distribution form the basis of, or be relied on in connection with, any action, contract, commitment or relating thereto or to the securities of Evogene or the Company.

The trademarks included herein are the property of the owners thereof and are used for reference purposes only. Such use should not be construed as an endorsement of our products or services.

2		2

About Evogene

4

DECODING BIOLOGY

OUR

PIONEER GROUNDBREAKING LIFE- SCIENCE PRODUCTS ROOTED IN MICROBES, SMALL MOLECULES, AND GENOMICS

5

MICROBES

SMALL MOLECULES

GENETIC ELEMENTS

Microbials for crops

Food

Human & animal probiotics

Plastic

degradation

Therapeutic microbials

Dietary supplements

Probiotics

Waste-water

treatments

Crop protection

Chemical stimulants

Animal fertility

Animal healthcare

Pharmaceuticals

Advanced wound care

Medical device coating

Alternative food

Improved crops

Bio fuel

Medical

Cannabis

Gene therapy

Cell therapy

Diagnostics & precision medicine

Novel

Chemicals

Source for

enzymes

Oil spill clearing

Flavors and Fragrances

enzymes

Fragrances	Natural food
	coloring

OF LIFE SCIENCE PRODUCT DEVELOPMENT

Low probability of success with high cost and long time-tomarket

Pharma

Industry

Cost of developing a single

pharmaceutical drug*

In the 1970's

$180M

In recent years

> $2,000M

Ag-chemicals

Industry

Years to develop a new crop

protection product**

1995

8Y

2000

9Y

2005-2008

10Y

2010-2014

11+Y

*Phillips McDougall, 2016. **https://www.forbes.com/sites/matthewherper/2017/10/16/the-cost-of-developing-drugs-is-insane-a-paper-that-argued-otherwise-was-insanely-bad/?sh=7533aa82d459

7

LIFE-SCIENCE PRODUCTS LONG-TAIL PROCESS

THE CHALLENGE

finding the winning candidates out of a vast number of possible prospects that address a complex myriad of criteria, to reach higher success rate for products

> DISCOVERY

> OPTIMIZATION

> DEVELOPMENT

> REGULATION

"Needle
in the		Approved
haystack"
	Product

T I M E / M O N E Y

8

TODAY WE

ARE ON THE

BRINK OF A

Computational technology advancements enable the discovery and optimization of the most promising candidates, addressing multiple development challenges towards successful life-science based products

LIFE-

SCIENCE

LIFE-SCIENCE PRODUCT DEVELOPMENT

Acceleration Optimization Efficiency

9

DECODING BIOLOGY

WE MERGE LIFE-SCIENCE WITH BIG DATA AND CUTTING- EDGE AI TECHNOLOGIES TO EFFECTIVELY DISCOVER

AND OPTIMIZE BREAKTHROUGH LIFE-SCIENCE BASED PRODUCTS